...
首页> 外文期刊>Online journal of biological sciences >Designing of Disulfide Cyclic Peptide for Inhibiting Polymerase A and Bl (PAC-PB1N) in H1N1 Virus using Molecular Simulation Approach
【24h】

Designing of Disulfide Cyclic Peptide for Inhibiting Polymerase A and Bl (PAC-PB1N) in H1N1 Virus using Molecular Simulation Approach

机译:使用分子模拟方法设计抑制H1N1病毒中聚合酶A和B1的PAC(PB1N)二硫键环肽

获取原文
获取原文并翻译 | 示例
           

摘要

The drug resistance A/H1N1 flu virus is emerging rapidly. Therefore, looking for potential therapy is very important. PB2, PB and PA are subunits of viral RNA-dependent RNA polymerase (RdRp). They play an important role in viral replication. The PA and PB1 binding sites can be considered as potential targets for the development of new influenza drugs. The peptide inhibitors can be designed specifically due to their high-preferred activity. In this study, the cyclic peptide ligands were designed basedon the crystal structure of PAC-PB1N in the surface of the molecule, resulting 1728 cyclopentadienyl compounds. The MOE 2008.10 software was utilized for molecular docking and dynamics simulation approach, while Lipinski's Rules of Five were utilized toevaluate the feasibility of drug candidates. Thus, molecular dynamics simulation was applied, in order to facilitate the interaction between the ligand and enzyme. The simulations have successfully produced two cyclopentyl peptides, namely CKKTC and CKTTC, which results in both ligands providing a potent inhibitor of polymerase PAC-PB1N of Influenza A/2009 (H1N1).
机译:耐药性A / H1N1流感病毒迅速出现。因此,寻找潜在的治疗方法非常重要。 PB2,PB和PA是病毒RNA依赖性RNA聚合酶(RdRp)的亚基。它们在病毒复制中起重要作用。 PA和PB1结合位点可被视为开发新型流感药物的潜在靶标。由于它们的高优先活性,可以专门设计肽抑制剂。在这项研究中,根据分子表面PAC-PB1N的晶体结构设计了环肽配体,得到了1728个环戊二烯基化合物。利用MOE 2008.10软件进行分子对接和动力学模拟,同时使用Lipinski的“ 5条规则”来评估候选药物的可行性。因此,为了促进配体和酶之间的相互作用,进行了分子动力学模拟。模拟成功地产生了两个环戊基肽,即CKKTC和CKTTC,这导致两个配体均提供了A / 2009流感(H1N1)聚合酶PAC-PB1N的有效抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号